Ocuphire Pharma Stock Gross Profit

OCUPDelisted Stock  USD 1.13  0.06  5.04%   
Ocuphire Pharma fundamentals help investors to digest information that contributes to Ocuphire Pharma's financial success or failures. It also enables traders to predict the movement of Ocuphire Stock. The fundamental analysis module provides a way to measure Ocuphire Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocuphire Pharma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Ocuphire Pharma Company Gross Profit Analysis

Ocuphire Pharma's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Ocuphire Pharma Gross Profit

    
  (14.58 M)  
Most of Ocuphire Pharma's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ocuphire Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, Ocuphire Pharma reported (14.58 Million) of gross profit. This is 100.65% lower than that of the Biotechnology sector and 101.53% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.05% higher than that of the company.

Ocuphire Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ocuphire Pharma's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ocuphire Pharma could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics of similar companies.
Ocuphire Pharma is currently under evaluation in gross profit category among its peers.

Ocuphire Fundamentals

About Ocuphire Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ocuphire Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocuphire Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocuphire Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Ocuphire Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ocuphire Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ocuphire Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Ocuphire Stock

  0.75CAT Caterpillar Fiscal Year End 3rd of February 2025 PairCorr
  0.68AXP American Express Fiscal Year End 24th of January 2025 PairCorr
  0.67WMT Walmart Aggressive PushPairCorr
  0.67AA Alcoa Corp Fiscal Year End 15th of January 2025 PairCorr
  0.66IBM International Business Fiscal Year End 22nd of January 2025 PairCorr
The ability to find closely correlated positions to Ocuphire Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ocuphire Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ocuphire Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ocuphire Pharma to buy it.
The correlation of Ocuphire Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ocuphire Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ocuphire Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ocuphire Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Ocuphire Stock

If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Bonds Directory
Find actively traded corporate debentures issued by US companies
Transaction History
View history of all your transactions and understand their impact on performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments